Optimal targeting of HER2-PI3K signaling in breast cancer: Mechanistic insights and clinical implications

Brent N. Rexer, Carlos L. Arteaga

Research output: Contribution to journalReview article

42 Scopus citations

Abstract

The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2+ breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed.

Original languageEnglish (US)
Pages (from-to)3817-3820
Number of pages4
JournalCancer Research
Volume73
Issue number13
DOIs
StatePublished - Jul 1 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Optimal targeting of HER2-PI3K signaling in breast cancer: Mechanistic insights and clinical implications'. Together they form a unique fingerprint.

  • Cite this